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Tea prepared from the aerial parts of Antigonon leptopus is used as a remedy for cold and pain relief in many countries. In this
study, A. leptopus tea, prepared from the dried aerial parts, was evaluated for lipid peroxidation (LPO) and cyclooxygenase (COX-
1 and COX-2) enzyme inhibitory activities. The tea as a dried extract inhibited LPO, COX-1 and COX-2 enzymes by 78%, 38%
and 89%, respectively, at 100 μg/mL. Bioassay-guided fractionation of the extract yielded a selective COX-2 enzyme inhibitory
phenolic aldehyde, 2,3,4-trihydroxy benzaldehyde. Also, it showed LPO inhibitory activity by 68.3% at 6.25 μg/mL. Therefore, we
have studied other hydroxy benzaldehydes and their methoxy analogs for LPO, COX-1 and COX-2 enzymes inhibitory activities
and found that compound 1 gave the highest COX-2 enzyme inhibitory activity as indicated by a 50% inhibitory concentration
(IC50) at 9.7 μg/mL. The analogs showed only marginal LPO activity at 6.25 μg/mL. The hydroxy analogs 6, 7 and 9 showed 55%,
61% and 43% of COX-2 inhibition at 100 μg/mL. However, hydroxy benzaldehydes 3 and 12 showed selective COX-1 inhibition
while compounds 4 and 10 gave little or no COX-2 enzyme inhibition at 100 μg/mL. At the same concentration, compounds 14,
21 and 22 inhibited COX-1 by 83, 85 and 70%, respectively. Similarly, compounds 18, 19 and 23 inhibited COX-2 by 68%, 72%
and 70%, at 100 μg/mL. This is the first report on the isolation of compound 1 from A. leptopus tea with selective COX-2 enzyme
and LPO inhibitory activities.
1. Introduction
The plant Antigonon leptopus is native to Mexico and
commonly found in tropical Asia, Africa, the Caribbean and
the Americas [1], and is one of the medicinal plants used in
Jamaica. The hot tea prepared from the aerial portion of this
plant is used traditionally for the prevention and treatment
of cough and flu-related pain (2Mitchell and Ahmad, 2006
S. A. Mitchell and M. H. Ahmad, A review of medicinal
plant research at the University of the West Indies, Jamaica,
West Indian Medicinal Journal 55 [2] (2006), pages 243–
253.). Studies have also shown that A. leptopus plant extracts
exhibited anti-thrombin, analgesic, anti-inflammatory, anti-
diabetic and lipid peroxidation inhibitory activities [2–5].
Phenolic compounds are widely distributed secondary
metabolites in the plant kingdom and play an important
role in their physiological and morphological functions
[6]. These compounds are diverse group of phytochemicals
derived from the shikimate and phenylpropanoid path-
ways in plants. Phenolic compounds are known as strong
antioxidants and might prevent antioxidative damage to
biomolecules such as DNA, lipids and proteins [7]. A
number of epidemiological studies have shown that phenolic
compounds can reduce the risk of chronic disorders such
as cardiovascular disease and cancer [8]. Also, the phenolic
compounds are reported to inhibit several stages of carcino-
genesis in vivo [9]. In addition, they possess significant anti-
inflammatory activity as suggested by both in vitro and in
vivo studies [10].
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the
most popular products used for pain management. The
NSAIDs act as inhibitors of prostaglandin synthesis by
cyclooxygenase (COX) enzymes. The COX enzymes catalyze
the conversion of arachidonic acid to prostaglandin endoper-
oxide, the immediate substrate, for a series of cell-specific
prostaglandins, which play critical roles in various biological
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functions [8]. The two isoforms of COX differ mainly in
their pattern of expression. COX-1 is expressed in most
tissues and COX-2 is an inducible enzyme that is expressed
in response to pro-inflammatory agents. Naturally occurring
selective COX-2 inhibitors are significant since they can
be consumed as supplements, reducing inflammation and
potentially preventing cancer [11–14]. In the present study,
we report the bioassay-guided isolation of a selective COX-2
inhibitor, a polyhydroxy benzaldehyde, from the tea extract
and LPO and COX assay results for the tea extract of A.
leptopus, the isolate and a number of its analogs.
2. Methods
2.1. Plant Material and Reagents. Aerial parts of A. leptopus
were collected in Jamaica during 2005 and authenticated by
Mr Patrick Lewis at University of the West Indies, Mona,
Kingston, Jamaica. A voucher specimen (UWI 35294) has
been deposited at the herbarium of the University of theWest
Indies, Mona, Kingston, Jamaica. The hydroxy benzalde-
hydes, 2-hydroxy benzaldehyde; 3-hydroxy benzaldehyde;
4-hydroxy benzaldehyde, 2,3-dihydroxy benzaldehyde; 2,4-
dihydroxy benzaldehyde, 2,5-dihydroxy benzaldehyde, 3,4-
dihydroxy benzaldehyde, 3,5-dihydroxy benzaldehyde, 2,4,5-
trihydroxy benzaldehyde, 2,4,6-trihydroxy benzaldehyde and
3,4,5-trihydroxy benzaldehyde, were purchased from Sigma-
Aldrich Chemical Co. (St Louis, MO).
2.2. Extraction and Isolation. Antigonon leptopus tea was
prepared from the dried aerial parts of the plant (5 g) by
soaking it with boiled water (50mL) for 6 h. The resulting tea
was evaporated under reduced pressure to yield a dark brown
residue (606mg). This residue was assayed LPO and COX
enzyme inhibitory activities at 100 μg/mL. This bioactive
extract was then analyzed by TLC using CHCl3 and MeOH
(4 : 1) as the mobile phase along with the methanolic extract
prepared earlier in our laboratory [5]. The TLC profiles of
tea residue and methanolic extract were similar except a
new band observed under UV (Rf . 0.63). In order to isolate
this UV-active compound, an aliquot of the water extract
(200mg) was purified by preparative TLC with CHCl3 and
MeOH (4 : 1) as the developing solvents afforded compound
1 (0.7mg). The structure of this compound was confirmed
by 1H and 13C NMR spectral methods.
Compound 1. 1H NMR (d6-DMSO): δ 9.83 (1H, s,
CHO), 7.107 (1H, d, J = 8.4Hz, H-6), 6.47 (1H, d, J =
8.4Hz, H-5), 10.67, 10.32, 8.77 (each 1H, OH); 13C NMR
(d6-DMSO): δ 193.1 (CHO), 153.2 (C-4), 150.9 (C-2), 132.2
(C-3), 123.7 (C-6), 115.4 (C-1), 108.3 (C-5). Therefore, the
structure of compound 1 was established as 2,3,4-trihydroxy
benzaldehyde and further confirmed by comparison of its
NMR chemical shifts with its published spectral data [15].
2.3. Methylation of Hydroxy Benzaldehydes. Methylation of
hydroxy benzaldehydes was performed according to pub-
lished procedure [16]. The monohydroxy benzaldehyde
(0.5mmol) was dissolved in 5mL of acetone in a round-
bottomed flask. To this solution, anhydrous potassium
carbonate (1mmol) was added, sealed with septa and stirred
for 10min. Dimethyl sulfate (1mmol) was then added to the
reaction mixture by injection, stirred at room temperature
for 6 h while monitoring the reaction by TLC for every
30min. The reaction mixture was evaporated under vacuum
and the residue dissolved in 25mL of RO water, transferred
to a separating funnel and extracted with ethyl acetate
(25mL), the ethyl acetate layer treated with saturated sodium
bicarbonate solution and evaporated under vacuum. The
product thus obtained was purified by preparative TLC using
chloroform :methanol (80 : 20) as the mobile phase. The
methylation of di- and trihydroxy benzaldehydes was carried
out by using a similar procedure but with 2 and 3mmols of
potassium carbonate and dimethyl sulfate, respectively. The
reaction times were 12 and 18 h for dihydroxy and trihydroxy
benzaldehydes, respectively. The yields of mono-, di- and
trimethoxy benzaldehydes were 90%, 86%, 75%, respectively.
The compounds were characterized by NMR spectral meth-
ods. The NMR spectra of hydroxy benzaldehydes purchased
from Sigma-Aldrich are not presented in this manuscript but
confirmed that the compounds were pure.
Compound 13. 1H NMR (d6-DMSO): δ 10.19 (1H, s,
CHO), 7.51 (1H, d, J = 9.0Hz, H-6), 7.00 (1H, d, J = 9.0Hz,
H-5), 3.98, 3.89, 3.89 (each 3H, s, OMe).
Compound 14. 1H NMR (d6-DMSO): δ 10.35 (1H, s,
CHO), 7.67 (1H, m, H-6), 7.22 (1H, d, J = 7.5Hz, H-4),
7.09 (2, d, J = 7.5Hz, H-3, 5), 3.90 (3H, s, OMe).
Compound 15. 1H NMR (d6-DMSO): δ 9.98 (1H, s,
CHO), 7.52 (2H, m, H-6, 5), 7.42 (1H, d, J = 1.5Hz, H-2),
7.29 (1H, m, H-4), 3.83 (3H, s, OMe).
Compound 16. 1H NMR (d6-DMSO): δ 9.87 (1H, s,
CHO), 7.87 (2H, d, J = 7.0Hz), 7.13 (2H, d, J = 7.0Hz),
3.86 (3H, s, OMe).
Compound 17. 1H NMR (d6-DMSO): δ 10.30 (1H, s,
CHO), 7.40 (1H, dd, J = 1.8, 7.8Hz, H-6), 7.26 (1H, dd,
1H, dd, J = 1.8, 7.8Hz, H-4), 7.02 (1H, d, J = 7.8Hz, H-5),
3.89, 3.98 (each 3H, s, OMe).
Compound 18. 1H NMR (d6-DMSO): δ 10.17 (1H, s,
CHO), 7.65 (1H, d, J = 8.7Hz, H-6), 6.69 (1H, d, J = 2.4Hz,
H-3), 6.32 (1H, dd, J = 8.7, 2.4Hz, H-5), 3.87, 3.90 (each
3H, s, OMe).
Compound 19. 1H NMR (d6-DMSO): δ 10.34 (1H, s,
CHO), 7.25 (1H, dd, J = 1.8, 9.0Hz, H-6), 7.21 (1H, brs,
H-5), 7.16 (1H, d, J = 9.0Hz, H-4), 3.87, 3.98 (each 3H, s,
OMe).
Compound 20. 1H NMR (d6-DMSO): δ 9.9 (1H, s,
CHO), 7.65 (1H, s, H-6), 7.55 (1H, s, H-2), 7.08 (1H, s, H-5),
3.8 (each 3H, s, 3, 4-OMe).
Compound 21. 1H NMR (d6-DMSO): δ 9.91 (1H, s,
CHO), 7.06 (2H, d, J = 2.4Hz, H-2, 6), Compound 22. 1H
NMR (d6-DMSO): δ 10.19 (1H, s, CHO), 7.15 (1H, s, 6-H),
6.79 (1H, s, 3-H), 3.92, 3.91, 3.73 (each 3H, s, OMe).
Compound 23. 1H NMR (d6-DMSO): δ 10.01 (1H, s,
CHO), 6.14 (1H, s, H-3, 5), 3.85 (3H, s, 4-OMe), 3.98 (6H,
s, 2.6-OMe).
Compound 24. 1H NMR (d6-DMSO): δ 9.88 (1H, s,
CHO), 7.26 (2H, s, H-2, 6), 3.86 (6H, s, 3, 5-OMe), 3.76 (3H,
s, 4-OMe).
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2.4. Cyclooxygenase Enzyme Inhibitory Assay. Cyclooxyge-
nase enzyme inhibitory assay was carried out according
to the published procedure [17]. The COX-1 enzyme was
prepared from ram seminal vesicles purchased from Oxford
Biomedical Research, Inc. (Oxford, MI). COX-2 enzyme was
prepared from insect cell lysate diluted with Tris buffer (pH
7) to yield an approximate final concentration of 1.5mg
protein/mL. Activities of phenolic compounds were assessed
by monitoring the initial rate of O2 uptake using a micro-
oxygen chamber and electrode (Instech Laboratories, Ply-
mouthMeetings, PA) attached to a YSImodel 5300 biological
oxygen monitor (Yellow springs Instrument, Inc., Yellow
Springs, OH) at 37◦C. Each assay mixture contained Tris
buffer (0.6mL, 0.1M, pH 7), phenol (1mM), hemoglobin
(85 μg) and DMSO or test samples (10 μL). Cyclooxygenase
enzymes (COX-1 or COX-2, 20 μL) were added to the
chamber and incubated for 3min and the reaction was
initiated by the addition of arachidonic acid (10 μL of a
1mg/mL solution). Analysis was performed in duplicate
for each sample and the standard deviation was calculated
for n = 2. The data were recorded using QuickLog for
windows data acquisition and control software (Strawberry
Tree, Inc., Sunnyvale, CA). The compounds 2–24 were tested
at 100 μg/mL concentration. The percent inhibition was
calculated with respect to DMSO control. Compound 1
was tested at 25 μg/mL and serial dilutions were made in
order to obtain dose—response curve. Non-steroidal anti-
inflammatory drugs, Aspirin (60 μM), Celebrex (26 nM)
and Vioxx (32 nM) were used as positive controls. Aspirin
was purchased from Sigma-Aldrich Co. (St. Louis, MO) and
Celebrex and Vioxx were physician samples kindly provided
by Dr Subash Gupta, Sparrow Pain Center, MI, USA. We
have used Vioxx as a positive control only in our in vitro
assays. We continue to use it as a positive control in in
vitro assays because Vioxx is a specific inhibitor of COX-2
enzyme among the non-steroidal anti-inflammatory agents
(NSAIDs) produced and marketed. The use of Vioxx as a
positive control in our in vitro assay is only for comparison
purposes and not intended as a treatment. It is only used to
study the mechanism of action of test compounds.
2.5. Lipid Peroxidation Inhibitory Assay. In vitro lipid
peroxidation assay was carried out using large unilamellar
vesicles (LUVs) using fluorescence spectroscopy according to
the published procedure [17]. The phospholipid, 1-stearoyl-
2-linoleoyl-sn-glycero-3-phosphatidylcholine (SLPC), in
CHCl3 and fluorescence probe, 3-[p-(6-phenyl)-1,3,5-hexa-
trienyl] phenylpropionic acid (DPH-PA), in DMF (mg/mL)
were homogenized and dried under reduced pressure. The
LUVs were produced by suspension of the lipid-probe
mixture (0.15M NaCl, 0.1mM EDTA and 0.01M MOPS
buffer maintained over Chelex resin) followed by ten freeze-
thaw cycles in a dry ice-EtOH bath and extrusion (29
times) through a 100 nm pore-size membrane (Avestin Inc.,
Ottawa, Canada). The final assay volume was 2mL,
consisting of 100 μL HEPES buffer (50mM HEPES and
50mM TRIS), 200 μL 1M NaCl, 1.64mL of N2-purged
water, 20 μL of test sample or DMSO and 20 μL of liposome
suspension. Lipid peroxidation was initiated by the addition
of 20 μL of FeCl2 · 4H2O (0.5mM) and the fluorescence
was monitored at 0min, 1min, 3min and every 3min up
to 21min using a Turner Model 450 Digital Fluorometer.
The decrease of relative fluorescence intensity over the
time was used to determine the rate of peroxidation. The
percentage of inhibition was calculated with respect to
DMSO control. Extracts were tested at 100 μg/mL. Pure
compounds were tested at 6.25 μg/mL since the activity of
compound 1 was >50%. Commercial antioxidants BHA
(butylated hydroxyanisol), BHT (butylated hydroxytoluene)
and TBHQ (t-butyl hydroquinone) were tested at 1 μg/mL.
3. Results
3.1. Bioactive Constituents in A. leptopus Tea. The crude
water extract obtained after evaporating the tea gave strong
LPO, COX-1 and COX-2 enzyme inhibitory activities as indi-
cated by 78%, 38.3% and 89%, respectively, at 100 μg/mL.
The bioassay-guided isolation of this extract gave a phe-
nolic compound with selective COX-2 enzyme inhibitory
activity. The structure of compound 1 was identified to be
2,3,4-trihydroxy benzaldehyde [1] by using NMR spectral
data and further confirmed by TLC comparison with an
authentic sample (Figure 1). It inhibited COX-2 enzyme by
90% and was inactive against COX-1 enzyme at 25 μg/mL
(Figure 2(a)). Serial dilutions of compound 1 were made
to determine the 50% inhibitory concentration. Therefore,
the dose-dependent evaluation of the inhibitory activity
of compound 1 against COX-2 enzyme gave the 50%
(IC50) inhibitory concentration as 9.7 μg/mL. Interestingly,
compound 1 did not show any activity against COX-1
enzyme at 500 μg/mL, the highest concentration tested.
3.2. Activity of Methoxylated Benzaldehydes. Although com-
pound 1 was isolated from A. leptopus tea as a natural
product, the synthetic version of it is available in the market
along with a number of other substituted hydroxyl benzalde-
hydes. Studies on antioxidant and anti-inflammatory activity
of some of the hydroxy benzaldehydes and their analogs
have been reported in the literature [18, 19]. Therefore, we
have compared the structure-activity relationship of some
of the commercially available hydroxy benzaldehydes (2–
12) with compound 1 along with their methoxy derivatives
(13–24) using in vitro LPO and COX enzyme inhibitory
assays. The hydroxyl benzaldehydes were methylated in our
laboratory to yield corresponding methoxy derivatives [15].
All compounds were characterized by proton and carbon
NMR experiments (Figure 1).
Among the monohydroxy tested, compound 3 selectively
inhibited COX-1 by 64% at 100 μg/mL. The inhibitory values
of compounds 14 and 15 against COX-1 and COX-2 enzymes
were 83% and 53% and 59% and 53%, respectively at
100 μg/mL (Figure 2(b)). Although compound 4 showed
little or no activity against COX enzymes, the methylated
product 16 inhibited COX-1 and COX-2 enzymes by 41%
and 65%, respectively, at 100 μg/mL (Figure 2(a)).
Among the dihydroxy benzaldehydes, compound 7 was
the most active against COX-2 enzyme with an inhibition of
61% at 100 μg/mL. Similarly, compounds 6 and 9 showed
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Figure 2: In vitro COX-1 and COX-2 enzyme inhibitory activities of: (a) hydroxyl benzaldehydes and (b) methoxy benzaldehydes. The
concentration of compound 1 tested in this assay was 25 and the tea extract and compounds 2–24 at 100 μg/mL. Positive controls used in the
assay were Aspirin (60 μM), and Celebrex (26 nM) and Vioxx (32 nM). DMSO was used as solvent control and the percent inhibition was
calculated with respect to DMSO control. Vertical bars represent average of two experiments ± SD.
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moderate inhibition against COX-2 enzyme by 55% and
43%, respectively. However, compounds 5 and 9 inhibited
COX-1 enzyme by 68% and 82%, respectively, at the same
concentration (Figure 2(a)). The COX-2 enzyme inhibitory
activity of compound 5 was increased to 64% after methyla-
tion as shown in Figure 2(a). Other methylated compounds,
18–21, showed little or no variation in the activity profile.
The inhibitory values observed for compounds 18, 19, 20 and
21 against COX-1 and COX-2 enzymes were 46%, 30%, 44%,
85% and 68%, 72%, 59%, 60%, respectively, at 100 μg/mL
(Figure 2(b)).
Among the trihydroxy benzaldehydes tested, compound
10 was not inhibitory to COX-1 and COX-2 enzymes when
tested at 100 μg/mL. However, its methylated product 22
inhibited COX-1 and COX-2 enzymes by 70% and 50%,
respectively, at the same concentration (Figure 2(b)). This
is evident from the activity profile of hydroxy benzaldehyde
11, a reversal of COX-1 and COX-2 activities due to
methylation from 86 and 16% at 100 μg/mL to 45% and
70%. Commercial standards Vioxx, Celebrex and aspirin
were tested at 32 nM, 26 nM and 60 μM concentrations.
The inhibition values of Aspirin and Celebrex against COX-
1 annd COX-2 enzymes were 69%, 41%, 27% and 72%,
respectively. Vioxx is inactive to COX-1 and inhibited COX-
2 enzyme by 91% (Figure 2(a)). The varying concentrations
of positive controls used were necessary to keep the COX
enzyme inhibition between 50% and 100%.
The LPO assay revealed that compounds 1 and 5 were the
most active and inhibited LPO by 68% and 64%, respectively,
at 6.25 μg/mL (Figure 3). The LPO inhibition observed for
compounds 2, 6 and 8 was in the range of 40%–45% at
the same concentration (data not shown). The methoxy
benzaldehydes showed little or no activity against LPO when
tested at 6.25 μg/mL. This is in agreement with the general
understanding that hydroxy group is essential for antioxidant
activity and methylation may result in lower activity [15].
Standard antioxidants BHA, BHT and TBHQ were used as
positive controls in the assay and the inhibition values were
in the range of 84%–93% for these compounds at 1 μg/mL
(Figure 3).
4. Discussion
Traditional use of the tea prepared from the aerial parts of
A. leptopus has been implicated to the alleviation of swelling
and cold. Studies have shown that the anti-inflammatory
activity of A. leptopus plant material was due to the presence
of phenolic compounds present in the organic extract [4, 5].
However, the constituents of the tea, the form consumed as
a remedy, and its biological activity have not been studied
till now. The results from the current study suggest that
several compounds present in the tea extract also exist in the
organic extract. The tea contained the phenolic compound
2,3,4-trihydroxy benzaldehyde with selective COX-2 enzyme
inhibitory activity.
Phenolic compounds have attracted considerable interest
in recent years due to their potential health benefits such as
anti-oxidant, antimicrobial, anti-inflammatory and cardio-














Figure 3: Lipid peroxidation inhibitory activities of tea prepared
from A. leptopus and compounds 1 and 5. Positive controls, antiox-
idants BHA (butylated hydroxyanisol), BHT (butylated hydroxy-
toluene) and TBHQ (t-butyl hydroquinone) were tested at 1 μg/mL.
Extract and compounds were tested 100, 6.25 μg/mL, respectively.
Water or DMSO was used as solvent control and the percent
inhibition was calculated with respect to water or DMSO control.
Vertical bars represent the average of two experiments ± SD.
protective activities [21–24]. The inhibition of prostaglandin
synthesis by phenolic compounds has also been reported
[25–27] and their COX inhibitory activity was correlated to
the antioxidant properties [27]. This observation is evident
from our COX assay results that benzaldehyde is inactive but
its hydroxylated analogs showed varying degrees of COX-1
and COX-2 enzyme inhibitory activities, although a trend
in activity related to the number of hydroxy and methoxy
substitutions were not evident.
The amount of aerial portions of A. leptopus used in the
preparation of tea and the frequency of its consumption by
folklore is unclear. Although the amount of A. leptopus plant
material used in the preparation of tea in our study was
primarily to yield adequate amount of extract for bioassay
and the isolation of bioactive principles, it is evident that a
tea prepared from 5 g of dried plant material deliver about
2.1mg of COX-2 active hydroxy benzaldehyde, compound 1.
This is in comparison to the efficacy of Vioxx observed in our
in vitro bioassay. Therefore, a 50% inhibitory concentration
(IC50) of 9.7 μg/mL observed for compound 1 is in par
with the 32 nM concentration of Vioxx. Hypothetically, the
consumption of A. leptopus tea containing 650–700mg of
extract containing compound 1 per day could yield COX-2-
related pain relief similar to the daily dose of an NSAID to a
person with an average body weight of 70 kg. In conclusion,
our efficacy results of the tea and active components present
in it support the use of A. leptopus tea as an ethnomedicine
to ameliorate inflammatory pain and may be beneficial to
improve the quality of life.
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